

## Julia Skokowa, MD/PhD

Full Professor, Head of the Division of Translational Oncology  
Department of Hematology, Oncology, and Clinical Immunology  
University Hospital Tuebingen, Tuebingen, Germany



### Personal Information

---

**Date of Birth** August 26<sup>th</sup>, 1975  
**ORCID number** 0000-0002-4399-2324  
**e-mail** julia.skokowa@med.uni-tuebingen.de

### Education

---

2003 PhD in Molecular Medicine, Dept. of Clinical Immunology, Hannover Medical School, Hannover, Germany  
2000 MD thesis, Dept. of Clinical Immunology, Hannover Medical School, Hannover, Germany  
1998 Medical Diploma, North-Ossetian Medical University, Vladikavkas, Russia

### Current Positions

---

2014 - Full Professor, Head Division of Translational Oncology  
Dept. of Hematology, Oncology, and Clinical Immunology, University Hospital Tuebingen, Tuebingen, Germany  
2006 - Head Reference Laboratory for Research, Diagnostics and Biobanking of the European Branch of the Severe Chronic Neutropenia International Registry (SCNIR)

### Academic Career

---

2014 - Full Professor of "Translational Oncology"  
Dept. of Hematology, Oncology, and Clinical Immunology, University Hospital Tuebingen, Tuebingen, Germany  
2012 Offer, Full Professor of 'Molecular Hematopoiesis', Hannover Medical School, Hannover, Germany  
2012 Offer, Full Professor of 'Stem Cells and Aging', Ulm University, Ulm, Germany  
2010 Offer, Full-time Faculty as Assistant Professor of Pediatric Hematology and Oncology, Weill Cornell Medical Center, Department of Pediatrics, New York, USA  
2010 - 2014 Assistant Professor of 'Experimental Hematology', Dept. of Molecular Hematopoiesis, Hannover Medical School, Hannover, Germany  
2006 - 2010 Research Group Leader  
Dept. of Molecular Hematopoiesis, Hannover Medical School, Hannover, Germany  
2004 - 2006 Postdoctoral Fellow  
Dept. of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany  
2002 - 2006 Clinical Resident  
Dept. of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany

### Awards

---

2019 Best Lecture Series in Molecular Medicine, University Hospital Tuebingen, Germany  
2015 Wuerttembergischer Cancer Award, Dres. Bayer - Stiftung, Germany  
2013 Cytokine Award, Hannover Medical School, Hannover, Germany  
2013 Best-of-ASH Abstract  
2013 Best-of-EHA Abstract  
2009 Best-of-ECI Abstract  
2009 Rudolf Schoen Award of the Hannover Medical School, Hannover, Germany  
2009 Fritz-Lampert Award of the German Society of Hematology and Oncology  
2007 Hans-Heinrich Niemann Award, Hannover Medical School, Hannover, Germany

2004 Hans-Hench Award for best PhD Thesis, German and Dutch Societies of Immunology  
2000 Honorary Lecture on behalf of the 75<sup>th</sup> Anniversary of the DAAD in the German Parliament

## Scientific activities

---

### Board member

#### International:

- Advisory Board of the Severe Chronic Neutropenia International Registry
- EuNet-INNOCHRON EU COST action manager
- Scientific Committee, the French National Cancer Institute
- Scientific Committee, the French National Agency of Research (ANR)

#### National:

- German Research Consortium MyPred, funded by the German Ministry of Education and Research
- Scientific sessions coordinator at the German Society of Hematology and Oncology (DGHO)
- Baden-Wuerttemberg HemPred (Predisposition for Hematological malignancies) Board

#### University Hospital Tuebingen/Medical Faculty of the University Tuebingen:

- Chair "Center of Gene and RNA Therapy Tübingen"
- Steering committee, Comprehensive Cancer Center Tuebingen - Stuttgart
- Member of the Faculty Council
- Deputy Dean of 'Molecular Medicine'
- Member, Executive Research Board
- Member, Center of Rare Diseases

### Reviewer/Editor

- Editor "Frontiers in Pediatrics"
- Abstract Reviewer of ASH Annual Meetings
- Abstract Reviewer of EHA (European Hematology Association) Annual Meetings
- Abstract Reviewer of the German Society of Hematology and Oncology (DGHO) Annual Meetings
- Reviewer of research grants of the German Scientific Board (DFG), the German Ministry of Education and Research (BMBF), the Dutch Cancer Society (KWF), the German-Israeli Foundation for Scientific Research and Development (GIF), the French National Cancer Institute, the French National Agency of Research (ANR), the Leukemia and Lymphoma Foundation, the Kay Kendall Leukaemia Fund (KKLF)
- Selected journals: Nature Medicine, Nature Genetics, Nature Communications, Blood, Blood Advances, Leukemia, British Journal of Haematology, Leukemia and Lymphoma, CRISPR Journal, Cells

## Professional Societies

---

- American Society of Hematology (ASH)
- European Hematology Association (EHA)
- International Society for Experimental Hematology (ISEH)
- American Society of Gene & Cell Therapy (ASGCT)
- International Society for Stem Cell Research (ISSCR)
- German Society of Immunology (DGfI)
- German Society of Hematology and Oncology (DGHO)
- German Society of Pediatric Hematology and Oncology (GPOH)

## Patents

---

1. WO 2008034637 A1 Methods involving LEF-1 regulation and use of LEF-1 or compounds altering LEF-1 signalling for treating or preventing diseases
2. WO 2010086185 A1 Vitamin B3/Nampt treatment of neutropenia
3. EP19217185 Novel G-CSF mimics and their applications
4. EP21158366 Method and composition for a targeted gene knockout using CRISPR/Cas9
5. EP21189707 Compound and method for a specific targeting of the *HAX1* gene
6. EP21184589 Compound and method for an allele-specific editing of the *ELANE* gene
7. EP21169352 Compound and method for the prophylaxis and treatment of leukemia

## Top 10 selected publications

---

1. **Skokowa, J.** Circumventing Mutation to Nix Neutropenia. **New England Journal of Medicine** 384, 1956-1958 (2021) editorial.
2. Dannemann, B., Klimiankou, M., Oswald, B., Solovyeva, A., Mardan, J., Nasri, M., Ritter, M., Zahabi, A., Arreba-Tutusa, P., Mir, P., Stein, F., Lachmann, N., Moritz, T., Morishima, T., Konantz, M., Lengerke, C., Ripperger, T., Steinemann, D., Erlacher, M., Niemeyer, C., Zeidler, K., Welte, K. & **Skokowa, J.** hiPSC Model of Stage-Specific Leukemogenesis in Severe Congenital Neutropenia reveals BAALC as a Key Oncogene. **Cell Stem Cell** 28, 906-922.e906 (2021).
3. Morishima, T., Krahl, A.C., Nasri, M., Xu, Y., Aghaallaei, N., Findik, B., Klimiankou, M., Ritter, M., Hartmann, M.D., Gloeckner, C.J., Stefanczyk, S., Lindner, C., Oswald, B., Bernhard, R., Hähnel, K., Hermanutz-Klein, U., Ebinger, M., Handgretinger, R., Casadei, N., Welte, K., Andre, M., Müller, P., Bajoghli, B. & **Skokowa, J.** LMO2 activation by deacetylation is indispensable for hematopoiesis and T-ALL leukemogenesis. **Blood** 134, 1159-1175 (2019).
4. **Skokowa, J.**, Dale, D.C., Touw, I.P., Zeidler, C. & Welte, K. Severe congenital neutropenias. **Nat Rev Dis Primers** 3, 17032 (2017).
5. **Skokowa, J.**, Steinemann, D., Katsman-Kuipers, J.E., Zeidler, C., Klimenkova, O., Klimiankou, M., Unalan, M., Kandabarau, S., Makaryan, V., Beekman, R., Behrens, K., Stocking, C., Obenauer, J., Schnittger, S., Kohlmann, A., Valkhof, M.G., Hoogenboezem, R., Gohring, G., Reinhardt, D., Schlegelberger, B., Stanulla, M., Vandenberghe, P., Donadieu, J., Zwaan, C.M., Touw, I.P., van den Heuvel-Eibrink, M.M., Dale, D.C. & Welte, K. Cooperativity of RUNX1 and CSF3R mutations in severe congenital neutropenia: a unique pathway in myeloid leukemogenesis. **Blood** 123, 2229-2237 (2014).
6. Klimenkova, O., Ellerbeck, W., Klimiankou, M., Unalan, M., Kandabarau, S., Gigina, A., Hussein, K., Zeidler, C., Welte, K. & **Skokowa, J.** A lack of secretory leukocyte protease inhibitor (SLPI) causes defects in granulocytic differentiation. **Blood** 123, 1239-1249 (2014).
7. Gupta, K., Kuznetsova, I., Klimenkova, O., Klimiankou, M., Meyer, J., Moore, M.A., Zeidler, C., Welte, K. & **Skokowa, J.** Bortezomib inhibits STAT5-dependent degradation of LEF-1, inducing granulocytic differentiation in congenital neutropenia CD34<sup>+</sup> cells. **Blood** 123, 2550-2561 (2014).
8. **Skokowa, J.**, Klimiankou, M., Klimenkova, O., Lan, D., Gupta, K., Hussein, K., Carrizosa, E., Kusnetsova, I., Li, Z., Sustmann, C., Ganser, A., Zeidler, C., Kreipe, H.H., Burkhardt, J., Grosschedl, R. & Welte, K. Interactions among HCLS1, HAX1 and LEF-1 proteins are essential for G-CSF-triggered granulopoiesis. **Nat Med** 18, 1550-1559 (2012).
9. **Skokowa, J.**, Lan, D., Thakur, B.K., Wang, F., Gupta, K., Cario, G., Brechlin, A.M., Schambach, A., Hinrichsen, L., Meyer, G., Gaestel, M., Stanulla, M., Tong, Q. & Welte, K. NAMPT is essential for the G-CSF-induced myeloid differentiation via a NAD(+)-sirtuin-1-dependent pathway. **Nat Med** 15, 151-158 (2009).
10. **Skokowa, J.**, Cario, G., Uenal, M., Schambach, A., Germeshausen, M., Battmer, K., Zeidler, C., Lehmann, U., Eder, M., Baum, C., Grosschedl, R., Stanulla, M., Scherr, M. & Welte, K. LEF-1 is crucial for neutrophil granulocytogenesis and its expression is severely reduced in congenital neutropenia. **Nat Med** 12, 1191-1197 (2006).